{"id":509,"date":"2020-09-02T10:28:11","date_gmt":"2020-09-02T10:28:11","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=509"},"modified":"2020-09-02T10:28:11","modified_gmt":"2020-09-02T10:28:11","slug":"31-aug-2020-interferons-ifn-%ce%b2-1b-significantly-increased-the-discharge-rate-at-day-14","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/31-aug-2020-interferons-ifn-%ce%b2-1b-significantly-increased-the-discharge-rate-at-day-14\/","title":{"rendered":"(31 Aug 2020) Interferons- IFN \u03b2-1b significantly increased the discharge rate at day 14"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.intimp.2020.106903<\/p>\n<p class=\"\">In this study (IRCT20100228003449N27), efficacy and safety of interferon (IFN) beta-1b in the treatment of patients with severe COVID-19 were evaluated.&nbsp; The primary outcome of the study was time to clinical improvement. Secondary outcomes were in-hospital complications and 28-daymortality. 80 patients were enrolled and finally 33 patients in each group completed the study. Time to clinical improvment in the IFN group was significantly shorter than the control group ([9(6-10) vs. 11(9-15) days respectively, p = 0.002, HR = 2.30; 95% CI: 1.33-3.39]). At day 14, the percentage of discharged patients was 78.79% and 54.55% in the IFN and control groups respectively (OR = 3.09; 95% CI: 1.05-9.11, p = 0.03). ICU admission rate in the control group was significantly higher than the IFN group (66.66% vs. 42.42%, p = 0.04). The duration of hospitalization and ICU stay were not significantly different between the groups All-cause 28-day mortality was 6.06% and 18.18% in the IFN and control groups respectively (p = 0.12). IFN beta-1b was effective in shortening the time to clinical improvement without serious adverse events in patients with severe COVID-19. Furthermore, admission in ICU and need for invasive mechanical ventilation decreased following administration of IFN beta-1b. Although 28-day mortality was lower in the IFN group, further randomized clinical trials with large sample size are needed for exact estimation of survival benefit of IFN beta-1b.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial https:\/\/doi.org\/10.1016\/j.intimp.2020.106903 In this study (IRCT20100228003449N27), efficacy and safety of interferon (IFN) beta-1b in the treatment of patients with severe COVID-19 were evaluated.&nbsp; The primary outcome of the study was&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/31-aug-2020-interferons-ifn-%ce%b2-1b-significantly-increased-the-discharge-rate-at-day-14\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(31 Aug 2020) Interferons- IFN \u03b2-1b significantly increased the discharge rate at day 14&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,30],"tags":[63],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/509"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=509"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/509\/revisions"}],"predecessor-version":[{"id":510,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/509\/revisions\/510"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}